Thursday, October 10, 2019 2:10:13 AM
https://oncologie.international/oncologie-announces-first-patient-enrolled-in-global-phase-2-study-of-bavituximab-plus-keytruda-pembrolizumab-for-advanced-gastric-or-gastroesophageal-cancer/
"– The initiated study will further evaluate the antitumor activity, safety and tolerability of bavituximab plus KEYTRUDA® in a gastric cancer population
– Oncologie’s first global study for bavituximab plans enrollment in the US, UK, Taiwan and South Korea
Boston and Shanghai, October 9th, 2019 – Oncologie, a biopharmaceutical company using an innovative precision medicine platform to develop next-generation oncology therapeutics, announced today the enrollment of the first patient in its global Phase 2 study of bavituximab in combination with Merck’s (known outside of the U.S. as MSD), anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with advanced gastric or gastroesophageal cancer.
Oncologie is collaborating with MSD in this clinical study to evaluate the combination of bavituximab and KEYTRUDA in patients with advanced gastric or gastroesophageal cancer. Bavituximab is a potential first-in-class investigational monoclonal antibody designed to block phosphatidylserine (PS) activation of multiple immune cell receptors, including T-cell immunoglobulin macrophage (TIM) and tumor-associated macrophage (TAM). The rationale to support this study was based on a previously reported retrospective analysis from over 90 patients who were enrolled in a Phase 3 lung cancer study, which demonstrated activity when Bavituximab was given prior to a PD-1 inhibitor.
“Initiating our first sponsored trial is a key milestone for Oncologie as it represents and highlights the progress we’ve made this year,” said Laura E. Benjamin, PhD, President and Chief Executive Officer at Oncologie. “This Phase 2 study is intended to further evaluate the antitumor activity and safety of bavituximab plus pembrolizumab in a gastric cancer population. We look forward to evaluating the potential this combination may provide globally.”
The Phase 2, multicenter, open-label, single-arm global study will assess the safety, tolerability, and efficacy of the investigational agent bavituximab in combination with pembrolizumab, a PD-1 inhibitor, in patients with advanced gastric and gastroesophageal cancer who have progressed on or after at least one prior standard therapy. The study is expected to enroll approximately 80 patients in the United States, United Kingdom, South Korea and Taiwan. The primary endpoint of the study will assess the antitumor activity of the combination, as well as safety and tolerability. In addition, other endpoints include evaluating drug levels, the effect of treatment on target proteins, and an exploratory analysis using Oncologie’s proprietary RNA biomarker signatures.
More information about this clinical study can be found at clinicaltrials.gov under NCT04099641 .
About Bavituximab
Bavituximab is an investigational chimeric monoclonal antibody that targets the activity of phosphatidylserine (PS). Bavituximab is believed to reverse PS-mediated immunosuppression by blocking the engagement of PS with its receptors, as well as by sending an alternate immune activating
signal. PS-targeting antibodies have been shown to shift the functions of immune cells in tumors, resulting in multiple signs of immune activation and anti-tumor immune responses. This mechanism may play an important role in allowing other cancer therapies to more effectively attack tumors by reversing the immunosuppression that limits the impact of those treatments. Importantly, bavituximab has also demonstrated a manageable safety and tolerability profile in previous clinical trials conducted to date, which may allow it to be combined effectively with other agents.
About Oncologie
Oncologie is a next generation, oncology therapeutics company. Oncologie leverages its unique biomarker platform to develop targeted therapies that are matched to individual tumors based on the dominant biology of the tumor microenvironment. The current pipeline is focused on mid-stage clinical programs that modify the immune system to enhance efficacy of current standards of care and emerging immunotherapy agents. Headquartered in Boston, Massachusetts and Shanghai, China, Oncologie is working with global partners to acquire and develop innovative drugs for cancer patients around the world. For more information on Oncologie, Inc., please visit WWW.ONCOLOGIE.INTERNATIONAL.".......
Recent MRK News
- European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer (NSCLC) at High Risk of Recurrence in Adults • Business Wire • 03/28/2024 10:45:00 AM
- GameStop Shares Tumble 20% in Pre-Market Trading Amid Revenue Decline, Direct Digital Plummets 42%, and More News • IH Market News • 03/27/2024 10:54:47 AM
- FDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1) • Business Wire • 03/26/2024 10:21:00 PM
- Merck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Maintenance LYNPARZA® (olaparib) for Certain Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer • Business Wire • 03/21/2024 10:45:00 AM
- Merck Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults • Business Wire • 03/19/2024 01:00:00 PM
- FarmSee Ltd Announces the Completion of a Minority Investment in its Swine Monitoring Platform • PR Newswire (US) • 03/15/2024 08:23:00 PM
- Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival (OS) Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer • Business Wire • 03/15/2024 10:45:00 AM
- Merck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9 • Business Wire • 03/13/2024 07:00:00 AM
- Merck Completes Acquisition of Harpoon Therapeutics, Inc. • Business Wire • 03/11/2024 12:15:00 PM
- Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24 • Business Wire • 03/06/2024 03:25:00 PM
- Futures Pointing To Continued Weakness On Wall Street • IH Market News • 03/05/2024 02:03:27 PM
- Merck to Participate in the Barclays 26th Annual Global Healthcare Conference • Business Wire • 03/05/2024 11:45:00 AM
- Merck to Participate in the Leerink Partners Global Biopharma Conference 2024 • Business Wire • 03/04/2024 11:45:00 AM
- Merck to Participate in the TD Cowen 44th Annual Health Care Conference • Business Wire • 02/27/2024 11:45:00 AM
- Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for the Treatment of Resectable NSCLC at High Risk of Recurrence • Business Wire • 02/23/2024 11:20:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2024 09:14:41 PM
- FDA Grants Priority Review to Merck's Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Primary Advanced or Recurrent Endometrial Carcinoma • Business Wire • 02/20/2024 11:45:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 09:03:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 09:01:31 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/14/2024 09:40:23 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/14/2024 09:30:41 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/14/2024 09:24:35 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/13/2024 09:50:19 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/13/2024 09:48:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/12/2024 09:03:49 PM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM